Order Article Reprints

Kuo H-Y, Han M-Z, Liao C-H, Lin Y-J, Wang C-T, Chen S-H, Chang T-T, Chen P-J, Lin S-H, Chen C-Y, et al. Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Pharmaceutics. 2022; 14(11):2263. https://doi.org/10.3390/pharmaceutics14112263

Kuo, Hsin-Yu, Meng-Zhi Han, Chih-Hsiang Liao, Yih-Jyh Lin, Chung-Teng Wang, Shang-Hung Chen, Ting-Tsung Chang, Po-Jun Chen, Sheng-Hsiang Lin, Chiung-Yu Chen, and et al. 2022. "Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma" Pharmaceutics 14, no. 11: 2263. https://doi.org/10.3390/pharmaceutics14112263

Kuo, H.-Y., Han, M.-Z., Liao, C.-H., Lin, Y.-J., Wang, C.-T., Chen, S.-H., Chang, T.-T., Chen, P.-J., Lin, S.-H., Chen, C.-Y., Chuang, C.-H., Wu, I.-C., Wu, J.-S., Hong, T.-C., Hsieh, M.-T., Lee, Y.-C., Wu, H.-T., & Tsai, H.-M. (2022). Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Pharmaceutics, 14(11), 2263. https://doi.org/10.3390/pharmaceutics14112263